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TO THE EDITOR
Se´zary syndrome (SS), mycosis fun-
goides (MF), and transformed mycosis
fungoides (TMF; Olsen et al., 2007)
belong to the heterogeneous group of
cutaneous T-cell lymphoma (CTCL).
They are characterized as extranodal
non-Hodgkin lymphoma from malig-
nant, mature T lymphocytes that home
to the skin and persist there (Girardi
et al., 2004). SS and MF are the most
common CTCL types. Recent genetic
and phenotypic studies suggest that MF
and SS, previously considered as diffe-
rent stages of the same disease, arise
from two distinct T-cell subsets (van
Doorn et al., 2009; Campbell et al.,
2010). Pathological diagnosis is often
hampered by the small proportion of
malignant cells and by the morphologi-
cal similarity to inflammatory skin
diseases (ISDs). Thus, a reliable cuta-
neous biomarker able to distinguish
malignant cells from reactive benign
T cells in the infiltrate of CTCL is still
needed. Most previous studies have
focused on blood malignant T lympho-
cytes in patients with leukemic disease
(Vonderheid et al., 2001; Ferenczi et al.,
2002; Su et al., 2003; Bensussan et al.,
2011). When skin samples were consi-
dered, a specific expression of EphA4,
Twist, TOX, PDCD1, or CDK158k/
KIR3DL2 gene was found in MF or SS
patients.
NKp46 has been shown on blood
malignant CD4þ T lymphocytes in SS
but not in MF or in TMF (Bensussan
et al., 2011). NKp46 belongs to naturalAccepted article preview online 30 July 2013; published online 29 August 2013
Abbreviations: CBCL, cutaneous B-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ISD, inflammatory
skin disease; LM, laser microdissection; NCR, natural cytotoxicity receptor; RT-PCR, real-time PCR; SEM,
standard error of the mean; SS, Se´zary syndrome; MF, mycosis fungoides; TMF, transformed mycosis
fungoides
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Figure 1. Transcriptional expression of NKp46 in epidermotropic T-cell lymphoma skin. (a) CD4, CD8, and CD56 immunostainings in skin biopsies from CTCLs
and ISDs. SS/MF/TMF pictures show massive dermal infiltration of CD4þ cells with epidermotropism, sparse CD8þ cells, and no CD 56þ cells. Bar¼300mm.
Histograms represent CD4þ , CD8þ , and CD56þ cell counts in each CTCL and ISD groups. Bars represent mean±SD. (b) qRT-PCR of NKp46 in CTCLs,
CBCLs, ISDs, and normal skin samples. Reference gene used for normalization was transcription factor IID/TATA-binding protein (TBP). The 2DDCTmethod was
used for mRNA quantification. mRNA from a Se´zary patient expressing NKp46 gene was used as the calibrator. Middle bar represents the mean of the group.
All data points represent the average of triplicate tests. NKp46 overexpression in CTCL, but not in ISDs, was also found when NKp46 expression was correlated to
CD4 expression. CBCL, cutaneous B-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ISD, inflammatory skin disease; MF, mycosis fungoides; qRT-PCR,
quantitative real-time PCR; SS, Se´zary syndrome; TMF, transformed mycosis fungoides.
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cytotoxicity receptors (NCRs), which
induce natural killer (NK)-cell activa-
tion upon binding to non-major
histocompatibility complex ligands.
Expressed on NK cells, regardless of
their state of activation, NKp46 is
directly involved in target-cell recogni-
tion and killing (Sivori et al., 1997).
We analyzed here NKp46 gene
expression in skin-resident CD4þ T
lymphocytes from epidermotropic
CTCL, cutaneous diffuse large B-cell
lymphoma, leg-type (CBCL), and ISDs.
The Institutional Ethics Committee
approved this study. Written informed
consent was provided according to the
Declaration of Helsinki Principles.
According to the French Law of August
2004–800 revised in 2011–814, each
patient was informed that the part of
their sample remaining after the diag-
nosis had been established could be
used for this research and that they
could oppose to this. No patients
opposed to the research use of their
remaining sample.
Included in this study were 15 CTCLs:
five MF, at stage IA with only patches
and plaques; five TMF, at stage IIA
(n¼ 2) and IIB (n¼3); and five SS:
at stage IVa with less than 1 year
evolution (male/female¼ 10/5; median
age 63 years, range 35–81). Controls
were 10 ISDs (five eczema, four psor-
iasis, one drug eruption; male/female¼
6/4; median age 57 years, range
31–85), five CBCLs (male/female¼3/2;
median age 74 years, range 71–83),
and five normal skin samples (male/
female¼3/2; median age 53 years,
range 43–56).
All biopsies were performed before
any treatment, because steroids or
methotrexate impairs NK-cell pheno-
type including NKp46 expression,
or they suppress NK-cell proliferation
(Chiossone et al., 2007; Dauguet et al.,
2010). Diagnoses were reviewed
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Figure 2. Transcriptional expression of NKp46 in cutaneous CD4+ laser-microdissected cells in epidermotropic T cell lymphomas. (a) PCR products of laser-
microdissected cells on agarose gel electrophoresis. CD4 and NKp46 mRNA are detected in SS, MF, and TMF, with a bright distinctive band at 128 and 86 bp,
respectively, but CD8 mRNA and CD56 mRNA are not detected. In ISDs and CBCLs, only CD4 mRNA is detected. (b) qRT-PCR of NKp46 in CD4þ laser-
microdissected cells in CTCLs, ISDs, and CBCLs. The median level of NKp46 mRNA in CD4þ laser-microdissected cells is higher in the nine pooled CTCLs when
compared with five CBCLs (Po0.05) or five ISDs (Po0.05). The reference gene used for normalization was the transcription factor IID/TATA-binding protein (TBP).
The 2-DDCT method was used for mRNA quantification. mRNA from a Se´zary patient expressing the NKp46 gene was used as the calibrator. Bars represents
mean±SD. CBCL, cutaneous B-cell lymphoma; CTCL, cutaneous T-cell lymphoma; ISD, inflammatory skin disease; MF, mycosis fungoides; PBMC, peripheral
blood mononuclear cell; qRT-PCR, quantitative real-time PCR; SNK, NK lymphoma cell lines; SS, Se´zary syndrome; TMF, transformed mycosis fungoides.
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according to the WHO-EORTC classi-
fication (Olsen et al., 2007).
Phenotypic analyses, performed on
formalin-fixed paraffin-embedded sec-
tions, showed that CD3þ lymphocytes
were prominent in dermal infiltrates
of all CTCLs. CD4þ was the major
T lymphocyte subtype with median cell
count/field of 95 (range 29–132) in SS,
94 (range 49–98) in MF, and 310 (range
101–352) in TMF. The CD4/CD8 ratios
were over 4:1 in all CTCLs (median 53,
range 7–372). CD56 cells were rare,
with median cell count/field of 0.1
(range 0–0.2) in SS, 0.2 (range 0–0.2)
in MF, and 0.1 in TMF (range 0–0.1;
Figure 1a). When compared with ISDs,
there was no significant difference,
because in ISDs the CD4þ median cell
count/field was 102 (range 70–130),
CD4/CD8 ratio was 1.5, and
CD56 median cell count/field was 3
(range 1–5).
NKp46 gene expression level was
assessed in whole tissue sections
using real-time (RT)-PCR. No significant
difference was found between SS,
MF, and TMF. However, we found a
significant overexpression of NKp46 in
the 15 CTCLs, with a median expre-
ssion level of 3.1 (range 0.56–8.17)
compared with ISDs (Po0.05), CBCLs
(Po0.05), or normal skin (Po0.05)
(Figure 1b). On agarose gel electrophor-
esis, a distinct bright band, only found in
the CTCL group, confirmed the RT-PCR
data. By using RT-PCR, we found that
T-plastin transcripts were detected at
similar levels in CTCL and ISD groups.
To ascertain whether NKp46 mRNA
expression level was linked to CD4þ
T lymphocytes, we laser-microdissected
immunostained CD4þ cells from
frozen skin sections (Supplementary
Figure S1a online). We checked the
laser-microdissected cells using end-
point reverse transcription PCR (CD3,
CD4 positive, CD8, CD56 negative) and
agarose gel electrophoresis (Figure 2a).
On performing quantitative RT-PCR
(qRT-PCR), the median NKp46 gene
expression level was found to be 7.3
(range 3.7–86.18) in the 15 CTCLs,
without significant difference across
MF–TMF–SS. In addition, NKp46 gene
expression levels in CD4þ laser-micro-
dissected cells were significantly
higher when CTCLs were compared
with CBCLs (Po0.05) and with ISDs
(Po0.05)(Figure 2b). T-plastin mRNA
was not expressed in CD4þ T lympho-
cytes from CTCL patients, although
it was reported in leukemic T cells
(Su et al., 2003).
Laser microdissection combined with
qRT-PCR enabled us to demonstrate that
NKp46 was overexpressed in CTCLs
only, and that NKp46 expression was
specifically found in laser-microdis-
sected CD4þ T lymphocytes from SS,
MF, and TMF. An aberrant NKp46
expression had been reported on circu-
lating Se´zary cells but not in circulating
cells of MF or TMF (Bensussan et al.,
2011). If, early in the evolution of MF
and TMF, malignant cell distribution is
restricted to the skin, NKp46 would only
be detected in skin-resident CD4þ T
lymphocytes and not in circulating
blood cells. Our results imply that
NKp46 specificity is not limited to SS
but extends to other epidermotropic
CTCLs, even at an early stage.
This aberrant NKp46 expression
recently reported in TMF skin, together
with other NK-specific receptors
(Ortonne et al., 2012), could be linked,
in the three types of CTCLs studied here,
to lymphocyte reprogramming toward a
NK phenotype (Meresse et al., 2006), an
hypothesis supported by expression of
cytotoxic proteins as granzyme B and
T cell–restricted intracellular antigen
in CTCL cells (Vermeer et al., 1999).
However, no alteration of the KIRs
and NKp46 gene locus on 19q13.4
was found using genomic microarrays
or array-based comparative genomic
hybridization. The transcriptional sig-
nature of this reprogramming could
result from induction of receptors and
adaptors normally restricted to the NK
lineage (Meresse et al., 2006). Another
cause for this aberrant expression of NK
markers in CTCL could be deregula-
tion of the transcription factor-E2A
implicated in T- and NK-cell lineage
development (Steininger et al., 2011).
Laser microdissection combined with
qPCR enabled us to identify NKp46
overexpression in skin-resident CD4þ
T lymphocytes from 15 CTCLs. In the
same patients, RT-PCR on whole tissue
sections enabled us to characterize a
significant NKp46 overexpression in
CTCLs and to distinguish them from
ISDs, CBCLs, or normal skin, with a
sensitivity and a specificity of 89% and
100%, respectively, and with a positive
predictive value of 100%. Therefore, as
long as a specific antibody is not avail-
able, RT-PCR on whole tissue sections
could be helpful for day-to-day diagno-
sis, particularly in the early stages of
epidermotropic CTCL. Further study on
large patient sample series will be
necessary to assess the value of NKp46
as a biomarker of epidermotropic CTCL.
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TO THE EDITOR
We read with great interest the recent
report regarding IL36RN mutations in
acute generalized exanthematous pustu-
losis (AGEP) by Navarini et al. (2013).
They analyzed IL36RN mutations in
96 cases with AGEP and found only
one homozygous mutation (p.Leu27Pro)
and three heterozygous mutations.
p.Leu27Pro is a founder mutation
causing generalized pustular psoriasis
(GPP) homozygously in African popula-
tions, and the AGEP patient described
by Navarini et al. (2013) with the
homozygous mutation p.Leu27Pro is
an African woman (Marrakchi et al.,
2011; Navarini et al., 2013). She had
a previous history of drug-induced
type-unknown skin reaction triggered
by uncertain antibiotics. She showed
pustules covering 85% of her body
surface, including the mouth, and a
39.4 1C fever triggered by amoxicillin.
A positive patch test to amoxicillin was
noted. Treatment of the patient was not
described. No recurrence was observed
during the 18-month follow-up.
In a recent report, we analyzed 11
patients with GPP not accompanied by
psoriasis vulgaris (PV) (GPP-alone;
Sugiura et al., 2013). Among the 11
GPP-alone patients, there was a
monozygotic twin with the compound
heterozygous mutations p.Arg10X and
p.Arg10ArgfsX1 in IL36RN whose
pustules and high fever had primarily
been triggered by amoxicillin.
The patients were 6-year-old Japanese
male identical twins. At the age of
2 years, they had erythema with pus-
tules on the whole body and fever over
38 1C after amoxicillin intake. In one of
the twins, blood examination revealed a
white blood cell count of 24,300ml1
and a C-reactive protein concentration
of 1.17 mg dl 1. Bacterial culture for
the pustules was negative. A skin biopsy
from a pustular eruption on the trunk
revealed a spongiform pustule of Kogoj
in the epidermis (Figure 1c). The results
of these examinations were similar to
those of the other twin. Patch tests were
conducted on one of the twins, and it
was found to be positive for amoxicillin.
Skin eruptions including pustules of the
twins were improved with a dosage of
6 mg kg1 oral cyclosporine. After the
first episode, each twin has episodic
systemic pustules unrelated to amoxicil-
lin intake (Figure 1a and b). Neither twin
has ever showed typical scaly erythema
corresponding to PV. The two patients,
monozygotic twins, had the compound
heterozygous mutations p.Arg10X and
p.Arg10ArgfsX1 in IL36RN (Sugiura
et al., 2013). Thus, they were
diagnosed as having GPP-alone with
IL36RN mutations that had once been
triggered by amoxicillin.
Amoxicillin- or penicillin-related drug-
induced GPP has been reported for a
long time, although the pathomechan-
isms of how penicillin induces GPP have
never been addressed (Ryan and Baker,Accepted article preview online 20 August 2013; published online 19 September 2013
Abbreviations: AGEP, acute generalized exanthematous pustulosis; DITRA, deficiency of IL-36 receptor
antagonist; GPP, generalized pustular psoriasis; IL36RN, IL-36 receptor antagonist; PV, psoriasis vulgaris
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